Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan
-
Published Date:
Jan 2021
-
Source:Emerg Infect Dis. 27(1):1-9
-
Language:English
-
[PDF-786.61 KB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:Rwanda and Bhutan, 2 low- and middle-income countries, implemented primarily school-based national human papillomavirus (HPV) vaccination in 2011 (Rwanda) and 2010 (Bhutan). We estimated vaccination effectiveness through urine-based HPV prevalence surveys in schools in 2013-2014 and 2017. In Rwanda, 912 participants from baseline surveys and 1,087 from repeat surveys were included, and in Bhutan, 973 participants from baseline surveys and 909 from repeat surveys were included. The overall effectiveness against vaccine-targeted HPV types (i.e., HPV-6/11/16/18) was 78% (95% CI 51%-90%) in Rwanda, and 88% (6%-99%) in Bhutan and against other α-9 types was 58% (21-78) in Rwanda and 63% (27-82) in Bhutan. No effect against other HPV types was detectable. Prevalence of vaccine-targeted HPV types decreased significantly, as well as that of other α-9 types, suggesting cross-protection. These findings provide direct evidence from low- and middle-income countries of the marked effectiveness of high-coverage school-based, national HPV vaccination programs.
-
Subject:
-
Pubmed ID:33350922
-
Pubmed Central ID:PMC7774553
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
image/gif 
image/jpeg 
image/gif 
image/jpeg 
image/gif 
image/jpeg 
application/pdf 
text/xml
No Related Documents.
Email
CDC-INFO
